Now Approved:

EPIDIOLEX® (cannabidiol) oral solution is indicated for the treatment of seizures associated with
Lennox-Gastaut syndrome or Dravet syndrome in patients 2 years of age and older.

To learn more, including important safety information and access to the full prescribing information, visit Epidiolex.com.

Our Story

We've achieved this distinction through innovation and persistence.

 

Medical Information

Access scientific and clinical information on Greenwich Biosciences products.

READ MORE

Spotlight News

Spotlight News
Apr 25, 2018
Greenwich Clinical Program Reflects Dedication to Scientific Rigor, Unmet Patient Needs
READ MORE >

Press Releases

Sep 27, 2018
Greenwich Biosciences Announces the DEA has Rescheduled EPIDIOLEX® (cannabidiol) Oral Solution to Schedule V
Read More >

Patients & Caregivers

“Our primary purpose is to make a positive and meaningful difference in the lives of patients and their caregivers.”

–Justin Gover,
Chief Executive Officer 

 

Careers

Become part of a dynamic, cutting-edge pharmaceutical company on the forefront of a new category of therapeutic treatment.